Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Neoplasm Metastasis
Interventions: DRUG: Temsirolimus (CCI-779) for 34 months|DRUG: Letrozole for 34 months
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer